# Red Light Therapy for Hair Growth: LLLT Evidence and Protocols > FDA-cleared home lasers have sham-controlled density gains. Not a transplant—often a multi-month adjunct. *Published 2026-07-10 · Updated 2026-07-10 · By Julian Hart* In short Home-use **FDA-cleared LLLT** for androgenetic alopecia has Grade A support from multiple double-blind RCTs and a 2021 meta-analysis (density SMD ≈ 1.27 vs sham). Typical: **~650–655 nm**, 3–4×/week, 16–26+ weeks. Adjunct—not transplant replacement. Red light for hair is one of the few consumer photobiomodulation claims with a real sham-controlled stack. Expectations still need adult supervision: months of sessions, modest density math, medical therapy when indicated. *This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.* ## What does the meta-analytic evidence show? Lueangarun et al. (2021) pooled double-blind RCTs of FDA-approved home LLLT devices and found significant hair density gains versus sham in men and women. Laser-diode-only devices edged some LED combinations in subgroup analysis. Form factors include combs, helmets, caps, and bands. Coverage and compliance may favor hands-free designs even when comb RCTs are classic. ## How should protocols be framed for readers? Think in courses: multi-week adherence beats one viral session. Wavelengths cluster near 650–655 nm; session energy is device-specific and should follow cleared labeling. Photograph scalp regions under consistent lighting monthly. Density is slow; early dropout is the main real-world failure mode. Key reference points ParameterTypical evidence range Wavelength~650–655 nm Frequency3–4× / week Course length16–26+ weeks Meta SMD density~1.27 vs sham SafetyMild local effects common RoleAdjunct, not transplant ## Where does LLLT sit among hair-loss options? Medical therapies (minoxidil, anti-androgens when appropriate) and procedures (transplants) occupy different effect-size tiers. LLLT is a non-drug adjunct with favorable safety. Dermatology care should rule out scarring alopecias and systemic causes before endless device shopping. ## What claims to reject? Reject overnight miracle regrowth, unregulated 'medical-grade' Amazon clones without clearance, and metabolic diabetes cures grafted onto hair-device marketing. Keep hair endpoints and glucose pilots in separate drawers. Sources: [Lueangarun 2021 LLLT hair meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC8675345/); [Powner Jeffery 2024 670 nm glucose pilot](https://onlinelibrary.wiley.com/doi/full/10.1002/jbio.202300521); [FDA device clearance context](https://www.fda.gov/). Readers should dual-source primary literature, translate slogans into exposure units and effect sizes, and rank interventions by expected value under uncertainty. Cheap reversible steps often outrank extreme protocols. Opportunity cost is real: hours spent on unvalidated tests are hours not spent on sleep, training, protein adequacy, and primary care. Sex, life stage, comorbidities, medications, and geography change interpretation. Prefer falsifiable claims with named endpoints over multi-disease cure lists. Update beliefs when stronger trials appear rather than freezing identity around a single paper or influencer narrative. Measured curiosity beats both panic and complacency. Further reading should prioritize primary sources and consensus documents over secondary social summaries. When evidence is mixed, state both the signal and the limits in the same paragraph. When evidence is strong, still avoid overclaiming universality across populations. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. ## Sources 1. [Lueangarun 2021 LLLT hair meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC8675345/) 2. [Powner Jeffery 2024 670 nm glucose pilot](https://onlinelibrary.wiley.com/doi/full/10.1002/jbio.202300521) 3. [FDA device clearance context](https://www.fda.gov/) --- Source: https://healthcanon.com/light-and-recovery/red-light-therapy-hair-growth Index: https://healthcanon.com/llms.txt · Full text: https://healthcanon.com/llms-full.txt